MedTrace Logo

Meropenem vs Cefotaxime as Empirical Treatment of SBP

NCT05427747 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 286

Last updated 2022-06-22

No results posted yet for this study

Summary

We aimed to evaluate whether meropenem is superior to cefotaxime for treatment of SBP empirically.

Conditions

  • Spontaneous Bacterial Peritonitis

Interventions

DRUG

cefotaxime

One group will be given cefotaxime and another group meropenem. The efficacy of antibiotic therapy will be checked with: * Follow-up paracentesis after 48 hours of initiation of empiric antibiotic treatment showing reduction in neutrophil count of at least 25% . * Decrease of peritoneal fluid PMN count to \< 250 cells/μ at end of treatment and negative previously positive ascitic fluid culture.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2024-01-31
Completion
2024-02-29

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05427747 on ClinicalTrials.gov